Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
Neoadjuvant Therapy and Biomarker Analysis of Stage II and III Breast Cancer With Docetaxel/Capecitabine and Celecoxib Followed by Doxorubicin/Cyclophosphamide and Celecoxib
Sponsor: National Cancer Institute (NCI)
Terminated
study drug was removed from the market and low enrollment.
Other terminated trials from National Cancer Institute (NCI)
Other Breast Cancer trials with similar outcome
This PHASE2 trial investigates Breast Cancer and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 10 recorded versions since 2004 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Oct 2023 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
-
Aug 2018 — Jan 2021 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Apr 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Nebraska
For direct contact, visit the study record on ClinicalTrials.gov .